BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Long-acting injectable iloperidone: Phase I started

Novartis began a Phase I trial to evaluate 2 formulations of long-acting injectable iloperidone. Under an amended 2004 deal, Novartis has exclusive rights from Vanda in the U.S. and Canada to develop and commercialize long-acting injectable iloperidone and ...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >